| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 9, 2013WATCHMAN® Device Continues to Demonstrate Positive Clinical Outcomes for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at https://www.tctmd.com/show.aspx?id=118115. PREVAIL...
-
Mar 6, 2013First Presentation of the Preliminary Results of All Three Co-Primary Endpoints to be Revealed During The American College of Cardiology 2013 Annual Scientific Sessions
The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the American...
-
Feb 12, 2013The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable...
-
Jan 29, 2013
Organizations Team up to Raise awareness and Make a Call to Action for European Governments to Develop Comprehensive Chronic Pain Treatment Programs Boston Scientific Corporation (NYSE: BSX) today...
-
Jan 16, 2013
The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Temperature...
-
Dec 17, 2012Company Begins Evaluation of its Next Generation Pacing Leads
The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial designed to establish the safety, performance...
-
Nov 30, 2012
The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the SYNERGY Stent...
-
Nov 20, 2012Devices Projected to Have up to Twice the Longevity of Comparable Products
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable...
-
Oct 31, 2012This Innovative Bioabsorbable Coating is the First to Complete Absorption Shortly after Drug Elution Ends at Three Months
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer)...
-
Oct 24, 2012
Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS Element™ Plus Coronary Stent Systems to include...
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element™ Everolimus-Eluting Platinum...
-
Oct 10, 2012
First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System REPRISE II Study Results Expected to Support CE Mark and Other...
-
Oct 8, 2012Pending Addition of Next Generation Mapping and Navigation System Would Expand Company Portfolio into Complex Electrophysiology Procedures
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions...
-
Aug 28, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's first and only commercially available...
-
Aug 28, 2012
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its PRECISION™ PLUS SPINAL CORD STIMULATOR (SCS) System in patients with the system and are in need for...
-
Aug 27, 2012
PRECISION™ PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its...
-
Aug 26, 2012Newly Revised European Society of Cardiology Guidelines Include LAA Closure Devices
European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients...
-
Aug 24, 2012RELIANCE® 4-FRONT™ Lead Designed to Streamline Surgical Procedure for Treatment of Heart Failure and Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable defibrillation lead now available in Europe and...
-
Jul 27, 2012First European Implants of INGENIO™ MRI Pacemaker with New Image Ready™ Technology Performed This Week
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance imaging (MRI) scan. Now...
-
Jul 2, 2012S-ICD® System selected as most innovative in the field of Electrophysiology and Cardiac Techniques
Attendees of Cardiostim 2012, a global medical conference held recently in Nice, France, have selected the S-ICD® System recently acquired by Boston Scientific Corporation (NYSE: BSX) as the most...
-
Jul 2, 2012Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug Administration (FDA) approval for the WATCHMAN® Left...
-
Jun 14, 2012Boston Scientific Announces First Patient Active with LATITUDE™ NXT Remote Patient Management SystemNext-generation wireless remote patient management system enabled for INGENIO™ family of pacemakers is now in use in Europe
Boston Scientific Corporation (NYSE: BSX) has initiated use of the LATITUDE NXT Remote Patient Management System with patients in Europe. Dr. Roberto Verlato, head of cardiology at Camposampiero...
-
Jun 8, 2012Adds First and Only Commercially Available Subcutaneous ICD Technology that Offers New Life-Saving Therapy Option to Patients at Risk of Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and...
-
May 18, 2012Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS...
-
May 15, 2012Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer
Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in...